Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients

Table 5 Comparison of outcomes of patients with Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma treated by various interventions

Study	Year	Number of patients	Interventions	Median OS, mo	1-, 3-, 5-yr
					DFS, %	OS, %
Llovet et al[9]	2008	299	Sorafenib	10.7	-	44/-/-1
		303	Placebo	7.9	-	33/-/-
Cheng et al[22]	2009	150	Sorafenib	6.5	-	53.3/-/-1
		76	Placebo	4.2	-	36.7/-/-1
Wörns et al[23]	2009	22	Sorafenib	3.3	-	-
Yau et al[24]	2009	51	Sorafenib	5.0	-	-
Ozenne et al[25]	2010	50	Sorafenib	5.5	-	-
Baek et al[26]	2011	201	Sorafenib	5.3	-	-
Iavarone et al[27]	2011	296	Sorafenib	10.51
Santini et al[28]	2012	93	Sorafenib	12.01
Zhao et al[29]	2013	222	Sorafenib and TACE	12.01
Minagawa et al[30]	2001	18	Liver resection			82/42/42
Chirica et al[31]	2008	20	Liver resection	32.0	40/20/171	73/56/451
Ishizawa et al[32]	2008	98	Liver resection		-/37/25	-/71/56
Wang et al[33]	2008	14	Liver resection	13.0		57/29/29
Torzilli et al[34]	2008	28	Liver resection		66/17/-	80/74/-
Yang et al[35]	2012	511	Liver resection	27.8	48/30/24	70/41/31
Torzilli et al[10]	2013	297	Liver resection		46/28/18	76/49/38
This study	2014	68	Liver resection	18.0	42/26/-	69/34/-
		34	Liver resection and Sorafenib	25.0	63/37/-	88/53/-

¹Including patients with BCLC-stage B. DFS: Disease-free survival; OS: Overall survival; TACE: Transarterial chemoembolization.